Mariana Oncology

Happy Holidays from all of us at Mariana Oncology! As we celebrate the season of joy and reflection, we wanted to extend our heartfelt gratitude to our partners and team members. May this holiday season bring you peace, happiness, and time with loved ones. Here’s to a healthy and prosperous New Year ahead!

Our approach to radioligand therapy (RLT) development is guided by a deep understanding of tumor target biology. We select targets that offer potential to address a range of cancers and tailor our drug design criteria for optimal target engagement and precise delivery of radioactive payloads to tumor sites, while minimizing impact on healthy tissues. Learn more about our approach to RLT design and development: https://brnw.ch/21wPlgv

We’ve made it to the final tribal council, and we’re taking home the NEVY Award for Powerhouse Life Science Company of the Year! This achievement is a true reflection of the passion, hard work, and vision of our incredible team. We’re so proud to be recognized for our contributions to biotech, and we’re even more excited for the future as we continue to innovate and improve healthcare solutions. A huge thank you to the New England Venture Capital Association (NEVCA), our partners, and everyone who has supported us along the way. #NEVYSurvivor #NEVCA #NEVYs24

We are honored to be nominated for the 2024 NEVY Award for Powerhouse Life Science Company of the Year! This year’s theme is Survivor, and much like the contestants on the show, our team thrives on collaboration, perseverance, and a relentless drive to overcome obstacles. We’re proud to be part of a community of innovators shaping the future of healthcare. Thank you to the New England Venture Capital Association (NEVCA) for the honor, we look forward to connecting with our fellow nominees at the House of Blues on December 5th! Learn more about the full list of nominees: https://brnw.ch/21wP89K #NEVYSurvivor #NEVCA #NEVYs24

Thanksgiving is the perfect time to express our gratitude for our dedicated team, partners, and the people living with cancer that we serve. Your support and collaboration inspire us every day as we strive to advance radiotherapy and improve cancer care. As you gather with loved ones, we encourage you to take a moment to reflect on what you’re thankful for. Wising you a joyful and peaceful Thanksgiving from all of us at #TeamMariana! #Thanksgiving #Gratitude #Oncology

Radioligand therapies are an emerging treatment modality that pairs the cancer-killing power of radiotherapy with the precision of targeted therapies. These treatments comprise a targeting compound or ligand designed to bind to a specific cancer marker, a radioisotope that emits radiation, and a chelator that strongly binds to and protects the radioisotope. The ligand directs the therapy to the target cancer cells and radiation emitted from the radioisotope causes critical damage to cancer cells. This targeted approach is designed to limit the impact of treatment on healthy cells, offering potential to improve the experience of treatment for patients. Learn more about our approach to radioligand therapy: https://brnw.ch/21wOXh0

#ICYMI: In October, we presented new preclinical data at #ENA24 that demonstrate the activity of our DLL3-targeted radioligand therapy in several tumor models, including those with low DLL3 expression levels, supporting its potential to address a range of solid tumors (Poster ENA24-152). #RLT #radioligandtherapy #oncology

Lung cancer is one of the most common cancers worldwide, with a significant unmet need for safe and effective treatment options. At Mariana Oncology, we are committed to advancing novel #radioligandtherapies (RLTs) with the potential to improve the experience of cancer treatment for patients with lung cancer and other solid tumors. Our portfolio of RLTs is designed to selectively address innovative cancer targets and deliver radiation directly to cancer cells, minimizing damage to healthy tissues. Learn more about lung cancer and how you can get involved this Lung Cancer Awareness Month: https://brnw.ch/21wOKjC #LCAM #LungCancerAwareness #CancerResearch

Our team enjoyed taking in pioneering research and engaging in conversations with peers advancing new approaches to radiopharmaceuticals, imaging agents, and detection technologies to improve the treatment of cancer and other serious diseases this week at the 37th Annual Congress of the European Association of Nuclear Medicine (EANM). #MarianaOnTheMove #Oncology #RadioligandTherapies #RLT

Visit our poster today at the 36th EORTC - European Organisation for Research and Treatment of Cancer-National Cancer Institute (NCI)-American Association for Cancer Research Symposium where we’re sharing preclinical data that confirms our DLL3-targeted radioligand therapy is active against DLL3, including in tumor models exhibiting low DLL3 expression. The results further support its potential to address a range of solid tumor indications as a novel treatment option. (Poster ENA24-152) #ENA2024 #RLT #radioligandtherapy #oncology